Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

MLA

Helena Furberg, et al. Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Apr. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6bd23cd5ba38335198128955b149a7cc&authtype=sso&custid=ns315887.

APA

Helena Furberg, Martin H. Voss, Robert J. Motzer, Chung-Han Lee, A. Ari Hakimi, Ritesh Kotecha, Fengshen Kuo, Jessica Scott, Michael T. Paris, Marina Mourtzakis, Oguz Akin, Joshua Chaim, Cihan Duzgol, Kate Weiss, Stacey Petruzella, Emily Stein, Andrea Knezevic, Sujata Patil, Alejandro Sanchez, & Yasser Ged. (2023). Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.

Chicago

Helena Furberg, Martin H. Voss, Robert J. Motzer, Chung-Han Lee, A. Ari Hakimi, Ritesh Kotecha, Fengshen Kuo, et al. 2023. “Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade,” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6bd23cd5ba38335198128955b149a7cc&authtype=sso&custid=ns315887.